What did Pfizer’s Lyme vaccine show?

Pfizer Lyme vaccine: efficacy signal, but regulatory hurdles ahead

Pfizer and Valneva’s Phase 3 program for a Lyme disease vaccine reported a strong reduction in the risk of developing Lyme disease, but the results created complications for regulators.

One report summarized that the vaccine cut cases by about 73% in the trial population, a major efficacy signal for a disease that can cause long-term symptoms and complications. However, the same coverage said the vaccine missed a primary statistical endpoint, which is often the key measure regulators use to judge whether a product demonstrates clear benefit.

A second report similarly described efficacy above 70% while noting that the trial did not clear the “primary” statistical hurdle. That combination—clinically meaningful point estimates paired with a technical shortfall—can force sponsors to pursue additional analyses, seek regulatory agreement on alternative endpoints, or generate further data depending on the regulator.

Why it matters:

• Lyme disease is common and prevention is limited. A vaccine that meaningfully reduces incidence could change how clinicians approach disease risk.
• Regulatory decisions depend on statistical criteria, not just effect size. Missing the primary endpoint can delay approval or narrow it to specific use conditions.
• This shapes next steps for the company and patients. Developers may pursue new data packages or redesigns so the evidence base meets required thresholds.

At this stage, the central takeaway is that the vaccine performed well against Lyme disease in trial outcomes, but the pathway to approval is “tricky” because of the missed primary endpoint.